Factory Mutual Insurance Co. Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Factory Mutual Insurance Co. lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 521,630 shares of the medical device company's stock after purchasing an additional 40,000 shares during the quarter. Factory Mutual Insurance Co. owned about 0.13% of DexCom worth $35,622,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Norges Bank purchased a new position in DexCom during the 4th quarter valued at $385,367,000. Congress Asset Management Co. boosted its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after acquiring an additional 1,332,522 shares during the period. Fisher Funds Management LTD purchased a new position in DexCom during the 4th quarter valued at $96,507,000. Woodline Partners LP purchased a new position in DexCom during the 4th quarter valued at $63,338,000. Finally, Northern Trust Corp raised its position in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president now owns 109,621 shares in the company, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now owns 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,536 shares of company stock valued at $1,393,876 in the last ninety days. Corporate insiders own 0.32% of the company's stock.

DexCom Stock Down 1.0%

NASDAQ:DXCM traded down $0.86 during mid-day trading on Friday, hitting $81.99. 2,904,075 shares of the company's stock traded hands, compared to its average volume of 4,350,358. The company has a fifty day moving average of $78.50 and a 200 day moving average of $79.32. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.91. The company has a market capitalization of $32.15 billion, a P/E ratio of 57.34, a P/E/G ratio of 2.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the company earned $0.32 earnings per share. The company's quarterly revenue was up 12.5% on a year-over-year basis. On average, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on DXCM shares. Citigroup reaffirmed a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. The Goldman Sachs Group started coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.32.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.